Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06639607 |
Title | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II) |
Acronym | PRiME II |
Recruitment | Not yet recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Washington University School of Medicine |
Indications | |
Therapies | |
Age Groups: | child | adult |
Covered Countries | USA |